Reported by Seoul Economic Daily / May 28, 2024.
Over 120 Sessions, 1,200 Papers, and Participation from Global Sleep Experts
The world's largest sleep conference, 'SLEEP 2024,' will take place from June 1 to 5 in Houston, Texas (local time). SLEEP 2024 is a medical conference of the Associated Professional Sleep Societies (APSS), which is organized by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), marking its 38th year this time.
Dr. Rebecca Spencer, Chair of the APSS Committee and neuroscientist at the University of Massachusetts Medical School, stated, “The SLEEP meeting brings together the world’s most respected experts in the fields of sleep medicine, sleep and circadian science, and sleep health. Unparalleled in scale, this gathering stands as the pinnacle event for the sleep field.”
The main themes of the 2024 Sleep Conference will include artificial intelligence (AI) for sleep clinics and clinical practice, new genetic discoveries in sleep and circadian science, and the diagnosis and treatment of sleep disorders. Over 120 sessions, more than 1,200 papers, and participation from around 135 global sleep industry companies are expected at the event.
Key sessions include a presentation by Dr. Yeilim Cho, a medical scientist at the U.S. Department of Veterans Affairs Puget Sound Health Care System, on June 2, discussing "The Glymphatic System and Cognition: Current Measures and Understanding" On June 3, Dr. Carlos Schenck, a professor and chief psychiatrist at Hennepin County Medical Center in Minnesota University, will lead a discussion on "Artificial Intelligence and Big Data in Sleep Medicine."
In the exhibition section, Avadel Pharmaceuticals (NASDAQ: AVDL), a pharmaceutical company, will showcase Lumryz, an FDA-approved treatment for narcolepsy, along with new clinical data. Zevra Therapeutics (NASDAQ: ZVRA), a company focused on developing treatments for rare diseases, plans to present data from its Phase 2 clinical trial for idiopathic hypersomnia and provide updates on its Phase 3 clinical trial.
Additionally, Panthera Dental, a Canadian medical device company, will display a customized oral device for the treatment of obstructive sleep apnea. HoneyNaps, which recently established a U.S. subsidiary in Boston, will present a poster on its paper titled "A Digital Therapy Based on Real-time Sleep Sensing Data," related to its second-generation digital therapy for insomnia (DTx), as well as its AI sleep disorder diagnosis solution, SOMNUM, which received FDA approval in August 2023.
Comments